Table 4.
Univariate analyses of outcome by prognostic factors
| Prognostic factor | % No HDM 5-year EFS ± SE (n) | % HDM 5-year EFS ± SE (n) | Hazard ratio | P |
|---|---|---|---|---|
| T-ALL | ||||
| Age, y | ||||
| Younger than 10 | 72.9 ± 4.9 (85) | 85.6 ± 4.1 (78) | 1.73 | .01 |
| 10 or older | 60.6 ± 6.3 (66) | 72.8 ± 5.6 (70) | ||
| WBC | ||||
| < 50 | 81.9 ± 5.1 (61) | 81.2 ± 5.2 (64) | 1.85 | .01 |
| ≥ 50 | 57.7 ± 5.4 (90) | 78.4 ± 4.6 (84) | ||
| NCI risk | ||||
| Standard | 83.9 ± 6.7 (31) | 86.8 ± 5.8 (38) | 2.21 | .01 |
| High | 63.3 ± 4.6 (120) | 77.1 ± 4.2(110) | ||
| Sex | ||||
| Male | 61.4 ± 4.8 (109) | 79.1 ± 4.0(111) | 0.56 | .03 |
| Female | 83.3 ± 5.8 (42) | 80.7 ± 6.8 (37) | ||
| Race | ||||
| White | 68.0 ± 4.5 (113) | 81.8 ± 3.7(116) | ||
| Black | 65.6 ± 8.6 (32) | 64.9 ± 11.6(23) | 1.49 | .33 |
| Other | 66.7 ± 19.3 (6) | 88.9 ± 10.5 (9) | 0.99 | |
| T-NHL | ||||
| Stage III | 88.1 ± 5.1 (43) | 79.9 ± 6.2 (45) | 0.69 | .43 |
| Stage IV | 87.0 ± 7.4 (23) | 88.0 ± 7.2 (26) |
T-ALL indicates T-cell acute lymphoblastic leukemia; T-NHL, T-cell lymphoblastic non-Hodgkin lymphoma; EFS, event-free survival; NCI, National Cancer Institute; and HDM, high-dose methotrexate.